Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study

BACKGROUND: Combined neoadjuvant chemotherapy with trastuzumab and pertuzumab is the standard regimen for human epidermal growth receptor 2 (HER2)-positive breast cancer (BC). However, pertuzumab is not available because it is not on the market or covered by medicare in some regions or poor economy....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haoqi, Li, Yuntao, Qi, Yixin, Zhao, Erbao, Kong, Xiangshun, Yang, Chao, Yang, Qiqi, Zhang, Chengyuan, Liu, Yueping, Song, Zhenchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304895/
https://www.ncbi.nlm.nih.gov/pubmed/35875123
http://dx.doi.org/10.3389/fonc.2022.909426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304895/
https://www.ncbi.nlm.nih.gov/pubmed/35875123
http://dx.doi.org/10.3389/fonc.2022.909426

Ejemplares similares